Navigation Links
Syracuse University partners with Serum Institute of India to develop vaccines for children
Date:9/4/2008

A unique partnership between Syracuse University and the Serum Institute of India could lead to better access to life-saving vaccines for children living in some of the most impoverished areas of the world. The Institute recently awarded $250,000 to a team of SU researchers led by Robert Doyle, assistant professor of chemistry in the College of Arts and Sciences, to develop new oral vaccines against tetanus and rotavirus, a severe form of diarrhea that affects infants and young children worldwide.

Tetanus is caused by a toxin produced by bacteria naturally found in soil. The vaccine is only available by injection. While the disease is rare in the Western world, tetanus caused an estimated 257,000 deaths in low-income countries between 2000 and 2003, according to the World Health Organization's (WHO) latest report. A significant percentage involved infants born in predominately rural areas who were exposed to the tetanus bacteria during unsanitary delivery procedures. Likewise, infants and young children in these same countries have a much higher risk of dying from rotavirus than those living in Western nations. The disease killed an estimated 500,000 children in developing nations during 2004, according to a 2007 WHO report.

"We are very excited to be working with the Serum Institute of India on these projects," Doyle says. "This is a difficult area of research due to the nature of the molecules we will be working with. But, if we are successful, our work could have an enormously positive impact on the lives of people well beyond Syracuse University. This is truly scholarship in action."

Founded in 1966, the Serum Institute of India produces and supplies low-cost, life-saving vaccines for children and adults living in low-income countries. It is the world's largest producer of measles and diphtheria-tetanus-pertussis (DPT) vaccines. An estimated two out of every three immunized children in the world have received a vaccine manufactured by the Serum Institute.

"Our company's philanthropic philosophy is to make high-quality, affordable, life-saving vaccines available for under-privileged children in both India and in more than 140 countries across the world," says S.V.Kapre, executive director of the Serum Institute of India. "This new partnership with Syracuse University will help the Serum Institute further this endeavor as it will open new doors of vaccine usage."

The Institute approached Doyle because of his successful research to develop an oral form of insulin, which may someday enable people with insulin-dependent diabetes to take fewer daily injections. An oral vaccine for tetanus would enhance distribution in impoverished countries. Doyle's team will also explore new ways to synthesize the rotavirus vaccine to make it more accessible to children in developing nations.

A new laboratory has been established in SU's Center for Science and Technology for the research, which poses a number of challenges. Similarly to insulin, the protein molecules used in the tetanus vaccine are destroyed in the digestive system. However, the tetanus molecules are 30 times larger than insulin, making them more difficult to transport. The vaccine is created by literally boiling the tetanus bacteria in a chemical solution, causing the protein to completely unfold. In its new, unfolded state, the tetanus protein is harmless, but is still recognized as tetanus by the immune system so as to trigger a response that protects the person from the disease.

"It's like frying an egg," Doyle says. "The egg white, which is a protein, is clear when you crack the egg into a pan. When the egg heats up, the egg white becomes opaque as the protein unfolds. You still recognize it as an egg, but you can't make the egg white clear again after it's been heated."

The challenge is to figure out how to package this large molecule, sneak it through the digestive system unharmed, and transport it through the wall of the small intestine where it can be absorbed into the bloodstream. "Tetanus is a strange and wonderful molecule," Doyle says. "We need to get a better idea of what the unfolded protein looks like and try to predict areas that would make good targets for attaching a transport vehicle."

Problem is, you can't actually see a protein molecule or the thousands of chemical reactions that take place within it over nanoseconds of time. However, researchers can develop computerized models of the molecules to predict their behavior and zoom in on possible targets. Damian Allis, research professor in the chemistry department, will be developing models for both projects. "The simulations allow us to view the process and identify sticky ends of the proteins that could potentially be used as binding sites for transport molecules," Allis says.

Unlike the tetanus vaccine molecule, the rotavirus molecule Doyle's team will be working with is not a protein; it is a viral capsulethe outer core of which is coated with proteins. "It's a totally different problem," Doyle says. "We need to deliver the viral capsid to the wall of the small intestine and keep it there long enough to trigger an immune response directly in the intestine, which is the first line of defense against the disease."

Current oral rotavirus vaccines use tiny amounts of weakened, live bacteria. The vaccines' possible side effects limit distribution in countries where access to health care is not readily available, according to the World Health Organization. Doyle's aim is to develop a vaccine that does not contain live bacteria and has fewer side effects. The results could lead to wider distribution in low-income countries, ultimately saving hundreds of thousands of lives.

"We have some strong ideas and some good people on our team who bring very different skill sets to these projects," Doyle says. "The University has been very supportive of this research. Every penny of the grant will go into research. It's now up to us; we are excited about the possibilities."


'/>"/>

Contact: Judy Holmes
jlholmes@syr.edu
315-443-8085
Syracuse University
Source:Eurekalert

Related biology news :

1. Syracuse University scientists discover how some bacteria may steal iron from their human hosts
2. Petascale climate modeling heats up at University of Miami
3. Tel Aviv University researchers create new stem cell screening tool
4. NC State first university in nation to offer canine bone marrow transplants
5. TGen and Washington University researchers discover new approach to treating endometrial cancer
6. Iowa State University researcher shows proteins have controlled motions
7. $2M grant awarded to University of Kentucky for research on nanoparticles and human health
8. Model for angelman syndrome developed by University of Texas at Austin biologists
9. Humans response to risk can be unnecessarily dangerous, finds Tel Aviv University study
10. Case Western Reserve University study looks at keeping migrant workers children healthy
11. Tel Aviv University researchers root out new and efficient crop plants
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/28/2016)... Synaptics (NASDAQ: SYNA ), a leading developer of human interface ... 31, 2015. --> --> ... percent compared to the comparable quarter last year to $470.5 million. ... million, or $0.93 per diluted share. --> ... of fiscal 2016 grew 9 percent over the prior year period ...
(Date:1/22/2016)... 22, 2016 ... of the  "Global Behavioral Biometric Market ... --> http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced ... Biometric Market 2016-2020"  report to their ... Markets ( http://www.researchandmarkets.com/research/4lmf2s/global_behavioral ) has announced the ...
(Date:1/20/2016)... Jan. 20, 2016   MedNet Solutions , an ... spectrum of clinical research, is pleased to announce the ... achievements are the result of the company,s laser focus ... eClinical , it,s comprehensive, easy-to-use and highly affordable ... --> Key MedNet growth achievements in 2015 include: ...
Breaking Biology News(10 mins):
(Date:2/4/2016)... Feb. 4, 2016  Sangamo BioSciences, Inc. (NASDAQ: ... today that Edward Lanphier , Sangamo,s president and ... progress of Sangamo,s ZFP Therapeutic ® development programs ... 2:40 pm ET on Thursday, February 11, 2016, at ... Conference. The conference is being held in ...
(Date:2/4/2016)... N.J. , Feb. 4, 2016  CytoSorbents ... immunotherapy leader commercializing its flagship CytoSorb® blood filter ... surgery patients around the world, announced that CEO ... present at the Source Capital Group,s 2016 Disruptive ... update on the company.  Conference ...
(Date:2/4/2016)...  Spherix Incorporated (Nasdaq: SPEX ) -- an intellectual property ... intellectual property, today provided an update on the Company,s ... of Texas and announcing that ... Partes Re-examination ("IPR") proceedings that VTech and Uniden ... initiated on only certain claims of two of the ...
(Date:2/4/2016)... ... ... Many of the engineers at FireflySci, Inc. have been manufacturing quartz and ... other cuvette manufacturers is their supercharged customer service and their extensive database of glass ... flow of inside information, they have recently revamped their manufacturing techniques to reduce lead ...
Breaking Biology Technology: